ALK FISH rearranged and amplified tumor with negative immunohistochemistry: A rare and challenging case concerning ALK status screening in lung cancer

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1514-1515

  Uguen, A ^a,b,c   Talagas, M ^b,c,d   Andrieu Key, S ^b   Costa, S ^b   Quintin Roue I ^b   De Braekeleer, M ^a,c,e   Marcorelles, P ^b,c,d  

^a INSERM   (France)

^b CHU MORVAN   (France)

^c UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALK GENE; ARTICLE; CANCER SCREENING; CASE REPORT; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; LUNG TUMOR; MALE; PROCEDURES;

PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84937679845     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv210     Document Type: Letter

References (5)

1. Ilie MI, Bence C, Hofman V et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol 2015; 26: 238-244.
2. Cabillic F, Gros A, Dugay F et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014; 9: 295-306.
3. Camidge DR, Theodoro M, Maxson DA et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012; 118:4486-4494.
4. Camidge DR, Skokan M, Kiatsimkul P et al. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer 2013; 119: 3968-3975.
5. Salido M, Pijuan L, Martinez-Aviles L et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011; 6:21-27.